This latest book in the Clinical Cases in Cardiology series presents a variety of commonly and rarely encountered cases associated with ?cardio-oncology. It explores the history of the discipline and each case described features concise practically orientated information on how to appropriately carry out physical examinations and utilize diagnostic tests including electrocardiography and monoclonal antibodies. Practically focused guidance is also provided on how to apply therapeutic techniques and the latest management strategies appropriately. 
Clinical Cases in Cardio-Oncology provides a concise practically applicable guide of how to diagnose and treat a range of conditions associated with ?cardio-oncology, making it a critical addition to the literature on the topic and a valuable resource for all medical practitioners who encounter these patients in their day-to-day practice.  

Dr Rohani qualified as a consultant cardiologist in 2006, training as an echocardiography fellow at McMaster University (2013) and currently works as an assistant professor at Northern Ontario School of Medicine, Canada. A passionate physician, who has dedicated many hours to learning, teaching and practicing cardiology, she has spent many long hours and into the night searching to discover, diagnose and treat patients with complex and rare symptoms and pathology. 

Autorentext
Dr Rohani qualified as a consultant cardiologist in 2006, training as an echocardiography fellow at McMaster University (2013) and currently works as an assistant professor at Northern Ontario School of Medicine, Canada. A passionate physician, who has dedicated many hours to learning, teaching and practicing cardiology, she has spent many long hours and into the night searching to discover, diagnose and treat patients with complex and rare symptoms and pathology. 

Inhalt

Dasatinib induced pleural effusion and pulmonary hypertension.- Ponatinib induced stroke.- Nilotinib induced Peripheral Artery Occlusive Disease.- Imatinib cardiotoxicity.- Doxorubicin induced heart failure with reduced ejection fraction.- Trastuzumab-related cardiotoxicity.- Rituximab, Doxorubicin or cancer induced tachycardia.- Carfilzomib (CFZ) induced heart failure with reduced ejection fraction.- Immune checkpoint inhibitor cardiovascular toxicities.- Androgen deprivation therapy cardiotoxicity.- 5 FU induced atrial fibrillation in the context of ischemic heart disease.- Cisplatin induced acute coronary syndrome.- Radiotherapy and valvular heart disease.- Acute coronary syndrome in a patient with lung cancer 2 days after second cycle of carboplatin and Paclitaxel.- Ibrutinib and cardiac arrythmias.- Dual therapy BRAF inhibitor chemotherapy (dabrafenib +Trametinib chemotherapy) induced peripheral edema.- Vascular endothelial growth factor (VEGF) Bevacizumab and hypertension.- Amyloid heart disease.- Venous thromboembolism in cancer patients.- QT prolongation in cancer patients.- Cardiovascular implantable electronic devices (CIEDs)in cancer patients needs radiation therapy.- Atrial fibrillation in cancer patients.- Pericardial disease in cancer patients.- Large cardiac mass, an incidental finding in a patient with breast cancer.